Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer

Amrane, Karim, MD*; Ollivier, Luc; Salaun, Pierre-Yves, MD, PhD‡§; Metges, Jean-Philippe, MD*; Abgral, Ronan, MD, PhD‡§

doi: 10.1097/RLU.0000000000002611
Interesting Images

FOLFIRI-aflibercept chemotherapy is indicated in second-line treatment of metastatic colorectal cancer (mCRC) after progression under FOLFOX (±bevacizumab). Nevertheless, its proven therapeutic efficacy in clinical trials was based on partial responses. And to date, only 2 cases of complete response assessed by CT were reported in literature. We report a complete metabolic response assessed by FDG PET/CT in a 50-year-old woman with mCRC treated by FOLFIRI-aflibercept. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC.

From the Departments of *Oncology,

Radiotherapy, and

Nuclear Medicine, University Hospital of Brest; and

§EA 3878 GETBO, IFR 148, Bretagne Loire University, Brest, France.

Received for publication December 2, 2018; revision accepted March 26, 2019.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Karim Amrane, MD, Department of Oncology, University Hospital of Brest, 2 Ave Foch, 29609 Brest Cedex, France. E-mail:

Online date: May 17, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.